Brussels, 4 May –
More than 1.4 billion people worldwide are living with elevated lipoprotein(a) [Lp(a)], an inherited, independent cardiovascular risk factor strongly linked to heart attacks, strokes, aortic stenosis, and premature cardiovascular events. Yet, only 1–2% of the population is tested. This staggering gap leaves millions vulnerable around the world and makes elevated Lp(a) one of the most under-recognised threats in global heart health.
The Brussels International Declaration on Lp(a) Testing and Management was co-created by the Lp(a) International Task Force, chaired by Prof. Florian Kronenberg, and global leaders at a Lp(a) Global Summit, held in Brussels, on March 24-25, 2025.
The Declaration presents a shared global vision for equitable, systematic Lp(a) testing and care integration in efforts to prevent cardiovascular disease and instead to promote cardiovascular health. It presents five clear, actionable asks for governments, health systems, and global institutions. It is designed to align with and strengthen international CVD prevention strategies across the globe, including efforts like the EU Cardiovascular Health Plan, the European Health Data Space, and emerging national cardiovascular health plans.
